The development of a multidisciplinary care pathway for patients with inflammatory bowel disease before, during and after pregnancy

Competing Interest Statement

EDD reports no conflicts of interest. SL reports no conflicts of interest. MC is coordinator of the BELpREG pregnancy registry in Belgium which received research grants from P&G Health, Tilman, UCB, Almirall, KelaPharma, Sanofi, and Johnson & Johnson. The companies providing research grants have no role in the design of the study; in collection, analysis, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. M.C. received speakers fees from UCB and KelaPharma, and a research grant from HRA Pharma; P.G. reports no conflicts of interest; T.L. reports no conflicts of interest; E.L. reports no conflicts of interest; A.P. reports no conflicts of interest. JD reports no conflicts of interest. CDH reports no conflicts of interest; A.M. reports no conflicts of interest; S.V. received lecture fees from AbbVie, Dr. Falk Pharma, Ferring, Hospira, MSD, Takeda and Tillotts; consultancy fees from AbbVie, AbolerIS Pharma, Alimentiv, Arena, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, Hospira, Imidomics, Janssen, Johnson and Johnson, Materia Prima, MiroBio, Morphic, MrMHealth, MSD, Mundipharma, Pfizer Inc, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance Biopharma, Tillots Pharma AG and Zealand Pharma; and grant/research support from AbbVie, Galapagos, MSD, Pfizer Inc and Takeda; JS received speakers fees from Pfizer, Abbvie, Ferring, Falk, Takeda, Janssen, Fresenius, and Galapagos; Consultancy fees from Pfizer, Janssen, Ferring, Fresenius, Abbvie, Galapagos, Celltrion, Pharmacosmos, and Pharmanovia; Research support from Galapagos and Viatris; B.V. received research support from AbbVie, Biora Therapeutics, Celltrion, Landos, Pfizer, Sossei Heptares, and Takeda. Additionally, B.V. received speaker's fees from AbbVie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Eli Lilly, Falk, Ferring, Galapagos, Johnson and Johnson, MSD, Pfizer, R-Biopharm, Sandoz, Takeda, Tillots Pharma, Truvion, and Viatris. Furthermore, B.V. received consultancy fees from AbbVie, Alfasigma, Alimentiv, Applied Strategic, AstraZeneca, Atheneum, BenevolentAI, Biora Therapeutics, Boxer Capital, Bristol Myers Squibb, Eli Lilly, Galapagos, Guidepont, Landos, Merck, Mylan, Nxera, Inotrem, Ipsos, Johnson and Johnson, Pfizer, Progenity, Sandoz, Sanofi, Santa Ana Bio, Sapphire Therapeutics, Sosei Heptares, Takeda, Tillots Pharma, and Viatris. Lastly, B.V. holds stock options in Vagustim. The companies providing research grants have no role in the design of the study; in collection, analysis, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. LL reports no conflicts of interest. KVC reports no conflicts of interest. MF received research grants from AbbVie, EG Pharma, Janssen, Pfizer, Takeda and Viatris; consultancy fees from AbbVie, AgomAb Therapeutics, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Merck Sharp and Dohme, MRM Health, Pfizer, Takeda and ThermoFisher; and speakers fees from AbbVie, Biogen, Boehringer Ingelheim, Dr Falk Pharma, Ferring, Janssen-Cilag, Merck Sharp and Dohme, Pfizer, Takeda, Truvion Healthcare and Viatris.

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics Committee Research of the University Hospitals / KU Leuven university in Leuven, Belgium gave ethical approval for this work (S53684 - MP022851).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes